Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502].

Autor: Wagner KR; Center for Genetic Muscle Disorders, Baltimore, Kennedy Krieger Institute, Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: wagnerk@kennedykrieger.org., Abdel-Hamid HZ; University of Pittsburgh, Pittsburgh, PA, USA., Mah JK; Cumming School of Medicine, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada., Campbell C; Department of Pediatrics, Clinical Neurological Sciences and Epidemiology, University of Western Ontario, Children's Hospital London Health Sciences Centre, London, ON, Canada., Guglieri M; The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Muntoni F; NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London, & Great Ormond Street Hospital Trust, London, UK., Takeshima Y; Hyogo College of Medicine, Nishinomiya, Hyogo, Japan., McDonald CM; Lawson Health Research Institute: Children's Hospital, London, ON, Canada., Kostera-Pruszczyk A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland., Karachunski P; University of Minnesota, Minneapolis, MN, USA., Butterfield RJ; University of Utah School of Medicine, Salt Lake City, UT, USA., Mercuri E; Paediatric Neurology, Catholic University, Rome, Italy; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Fiorillo C; IRCCS Giannina Gaslini, Genova, Italy., Bertini ES; Bambino Gesu Children's Research Hospital IRCCS, Rome, Italy., Tian C; Cincinnati Children's Hospital Medical Center; College of Medicine University of Cincinnati, Cincinnati, OH, USA., Statland J; University of Kansas Medical Center, Kansas City, KS, USA., Sadosky AB; Pfizer Inc, New York, NY, USA., Purohit VS; Pfizer Inc, Cambridge, MA, USA., Sherlock SP; Pfizer Inc, Cambridge, MA, USA., Palmer JP; Pfizer Inc, Cambridge, MA, USA., Binks M; Pfizer Inc, Cambridge, MA, USA., Charnas L; Pfizer Inc, Cambridge, MA, USA., Marraffino S; Pfizer Inc, Cambridge, MA, USA., Wong BL; University of Massachusetts Medical School, Worcester, MA, USA.
Jazyk: angličtina
Zdroj: Neuromuscular disorders : NMD [Neuromuscul Disord] 2021 Feb; Vol. 31 (2), pp. 167-168. Date of Electronic Publication: 2021 Jan 13.
DOI: 10.1016/j.nmd.2021.01.001
Databáze: MEDLINE